Inwound
Scandinavian medical device startup developing optical therapies and imaging systems for dermatology and wound care. The company focuses on high-power, multi-wavelength light therapy to eradicate bacteria (including biofilm) in tissue while stimulating cellular repair, and on handheld multimodal imaging for visual, fluorescence and thermal assessment. Products are developed in-house, have completed clinical safety testing, and the company reports FDA clearance for its therapeutic device and ISO 13485 certification for production.
Industries
Nr. of Employees
small (1-50)
Products
Antimicrobial multi-wavelength light therapy device (Class II medical device)
A non-invasive, high-power optical therapeutic device that delivers selected wavelengths (including high-power blue light) to eradicate bacteria and biofilm in tissue while stimulating cellular repair processes; described as a Class II medical device with reported FDA premarket documentation and clinical use.
Handheld multimodal clinical imaging device (visual, fluorescence, thermal)
Portable imaging device capable of high-resolution visible imaging, fluorescence imaging for biological signals, thermal imaging, and distance measurement to assist clinical assessment.
FlashHeal
FlashHeal dramatically improves a wide array of dermatology disorders by applying energy in the form of light to the affected area, reducing bacteria while stimulating ATP production and increasing blood flow.
MIMR System
MIMR Optics is a hand-held device for advanced imaging needs, offering high-resolution standard images, distance measurement, bioluminescence (fluorescence) imaging, and thermal imaging.
Antimicrobial multi-wavelength light therapy device (Class II medical device)
A non-invasive, high-power optical therapeutic device that delivers selected wavelengths (including high-power blue light) to eradicate bacteria and biofilm in tissue while stimulating cellular repair processes; described as a Class II medical device with reported FDA premarket documentation and clinical use.
Handheld multimodal clinical imaging device (visual, fluorescence, thermal)
Portable imaging device capable of high-resolution visible imaging, fluorescence imaging for biological signals, thermal imaging, and distance measurement to assist clinical assessment.
FlashHeal
FlashHeal dramatically improves a wide array of dermatology disorders by applying energy in the form of light to the affected area, reducing bacteria while stimulating ATP production and increasing blood flow.
MIMR System
MIMR Optics is a hand-held device for advanced imaging needs, offering high-resolution standard images, distance measurement, bioluminescence (fluorescence) imaging, and thermal imaging.
Services
Clinical rollout and support for therapeutic and imaging devices in independent clinics and hospitals; clinician support and technical contact for healthcare professionals.
Clinical rollout and support for therapeutic and imaging devices in independent clinics and hospitals; clinician support and technical contact for healthcare professionals.
Expertise Areas
- Antimicrobial phototherapy
- Photobiomodulation and cellular bioenergetics
- Medical device development and engineering
- Optical and multimodal imaging systems
Key Technologies
- High-power blue-light therapy
- Multi-wavelength photobiomodulation
- Reactive oxygen species–mediated antimicrobial mechanism
- Fluorescence (bioluminescence) imaging
News & Updates
Company obtained ISO 13485 certification for production of medical devices.
Reported FDA clearance for the therapeutic Class II device; premaket submission referenced (K233077) and listed FDA approval in 2024.
Received Eurostars grant of EUR 1.2M to develop the therapeutic device.
Received EIT Health grant and Innobooster grant to support product development.
Early-stage awards including Best Medtech Idea at CareWare and winners at Venture Cup Denmark and International Venture Cup.
Started clinical safety testing in 2023; first patients treated at two clinics in Miami, Florida in 2025.
Company obtained ISO 13485 certification for production of medical devices.
Reported FDA clearance for the therapeutic Class II device; premaket submission referenced (K233077) and listed FDA approval in 2024.
Received Eurostars grant of EUR 1.2M to develop the therapeutic device.
Received EIT Health grant and Innobooster grant to support product development.
Early-stage awards including Best Medtech Idea at CareWare and winners at Venture Cup Denmark and International Venture Cup.
Started clinical safety testing in 2023; first patients treated at two clinics in Miami, Florida in 2025.